Longevity & AgingArticolo di ricercaA pagamento

Screen of aged human cells flags splicing factor SRSF1 as a lever on aging in mice

A cDNA screen using a transcriptomic age clock found SRSF1 rejuvenates aged cells and was linked to slower frailty and longer median lifespan in mice.

lunedì 16 novembre 2026 1 visualizzazione
Pubblicato in Nat Aging
Glowing SRSF1 splicing-factor protein binding a strand of RNA, with a youthful cell emerging from a wrinkled aged one

Riepilogo

Researchers built a transcriptomic age predictor for human skin fibroblasts and used it to screen cDNA overexpression candidates for factors that make aged cells look younger without erasing cell identity. The screen flagged SRSF1, an RNA-splicing and processing factor. Switching on SRSF1 in cultured cells reduced senescence, protein-folding stress and inflammatory signaling. In aged mice, inducible SRSF1 expression reduced frailty progression by 44% and was associated with a 14% longer median lifespan, though groups were small (9-10 animals each). The work points to a possible alternative to Yamanaka-factor partial reprogramming, which faces toxicity and efficacy concerns. This is early preclinical research. Several authors also hold a related patent and equity in a company developing aging therapeutics.

Riepilogo Dettagliato

Partial reprogramming with Yamanaka factors can reset some molecular signatures of aging and improve cell function. Toxicity and efficacy concerns limit its use in living animals and people. That has driven a search for other interventions that can shift aged cells toward a younger state while keeping their identity intact.

The team first built an interpretable transcriptomic age predictor in human fibroblasts. They then ran a cDNA overexpression screen, testing which individual factors pushed aged gene-expression profiles toward youthful patterns. The top hit was SRSF1, an RNA-processing and splicing factor.

In cultured cells, SRSF1 induction produced robust youthful transcriptional signatures without loss of cellular identity. It also reduced senescence, proteostatic stress and inflammatory signaling. In aged mice, inducible SRSF1 expression reduced frailty progression by 44% and was associated with a 14% extension of median lifespan, using 9-10 animals per group. The authors describe SRSF1 as a conserved regulator of aging and a promising geroprotective target.

If the findings hold up, targeting RNA splicing and processing could be a route to rejuvenation that avoids full reprogramming. A clock-guided screen like this one could also be reused to find other candidates.

There are important caveats. This summary relies only on the abstract, so details such as mouse strain, sex, statistical treatment, maximum lifespan and safety data are unavailable. The animal groups are small, and the fibroblast-based screen may not capture aging in other tissues. Sustained SRSF1 expression could carry risks, since splicing dysregulation is linked to disease and cancer biology. Several authors are named inventors on a patent covering SRSF1 and hold equity in RegulaBio, so independent replication will matter. Any human application is a long way off.

Risultati Principali

  • A transcriptomic age predictor in human fibroblasts guided a cDNA overexpression screen for factors that shift aged cells toward youthful expression.
  • The screen identified the splicing factor SRSF1, which produced youthful transcriptional signatures without loss of cellular identity.
  • In cells, SRSF1 induction reduced senescence, proteostatic stress and inflammatory signaling.
  • In aged mice, inducible SRSF1 reduced frailty progression by 44% and was associated with a 14% longer median lifespan.
  • Mouse groups were small (n = 9-10), and authors disclose a patent and company equity related to SRSF1.

Metodologia

The authors developed an interpretable transcriptomic age predictor in human fibroblasts and used it to run a cDNA overexpression screen. Top candidate SRSF1 was tested in vitro for senescence, proteostatic stress and inflammatory signaling. It was then tested in aged mice with inducible expression, measuring frailty progression and median lifespan (n = 9-10 per group).

Limitazioni dello Studio

Only the abstract was available, so mouse strain, sex, statistics, safety and tissue-level effects could not be assessed. Groups of 9-10 mice are small for lifespan claims, and the 14% median extension needs replication. Authors hold a patent and equity in RegulaBio, and the screen was done in fibroblasts, which may not generalize to other tissues.

Ti è piaciuto questo riepilogo?

Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.

Inserisci la tua email per iscriverti: